Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition.
Front Oncol
January 2025
Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
Background: Dedifferentiated liposarcoma (DDLPS) is a rare mesenchymal cancer originating from the adipose tissue, with poor survival rates for most patients, highlighting the critical need for novel treatment options.
Case Description: This report examines the efficacy and safety of sequential pre-treatment with the marine-derived alkaloid trabectedin followed by checkpoint inhibition using the anti-PD-1 antibody nivolumab in a 63-year-old male patient with unresectable retroperitoneal DDLPS. Treatment was initiated at the time of the seventh relapse as part of the NitraSarc phase 2 multicenter trial for inoperable soft tissue sarcoma conducted by the German Interdisciplinary Sarcoma Group (GISG-15, ).
Integrating knowledge-based planning and noncoplanar oblique VMAT arcs: A study of dose to the heart and immune cells in thoracic radiotherapy.
Tech Innov Patient Support Radiat Oncol
March 2025
Department of Radiation Oncology, Emory University, Atlanta, GA, USA.
Background: Recent patient studies have linked higher immune cell doses with worse quality of life and survival. For thoracic radiotherapy, heart dose is a major contributor to the effective dose to immune cells (EDIC).
Purpose: This study investigates heart and immune cell doses for plans optimized using a cardiac-sparing knowledge-based planning (KBP) model and the impact of carefully crafted beam geometry.
Evaluating the influence of anti-PD-1 immunotherapy combined with IMRT on thyroid dysfunction in nasopharyngeal carcinoma.
Front Immunol
January 2025
The Second Clinical Medical College of Jinan University, Department of Radiotherapy, Shenzhen People's Hospital, Shenzhen, Guangdong, China.
Background: Immunotherapy represents a major breakthrough in malignant tumor treatment in recent years. Anti-PD-1 immunotherapy has significantly prolonged Event-free Survival (EFS) in Nasopharyngeal Carcinoma (NPC). However, its potent anti-tumor effects can also attack normal tissues and organs, leading to immune-related adverse effects (irAE), with the thyroid being one of the most commonly affected organs.
View Article and Find Full Text PDFFeasibility and time gain of implementing artificial intelligence-based delineation tools in daily magnetic resonance image-guided adaptive prostate cancer radiotherapy.
Phys Imaging Radiat Oncol
January 2025
Department of Clinical Research, University of Southern Denmark, Denmark.
Background And Purpose: Daily magnetic resonance image (MRI)-guided radiotherapy plan adaptation requires time-consuming manual contour edits of targets and organs at risk in the online workflow. Recent advances in auto-segmentation promise to deliver high-quality delineations within a short time frame. However, the actual time benefit in a clinical setting is unknown.
View Article and Find Full Text PDFNomogram based on dual-energy computed tomography to predict the response to induction chemotherapy in patients with nasopharyngeal carcinoma: a two-center study.
Cancer Imaging
January 2025
Department of Radiology, Chongqing University Cancer Hospital, Chongqing, China.
Background: Previous studies utilizing dual-energy CT (DECT) for evaluating treatment efficacy in nasopharyngeal cancinoma (NPC) are limited. This study aimed to investigate whether the parameters from DECT can predict the response to induction chemotherapy in NPC patients in two centers.
Methods: This two-center retrospective study included patients diagnosed with NPC who underwent contrast-enhanced DECT between March 2019 and November 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!